













Gastric Lesions


Kingston Health Sciences Centre



















Faculty/Presenter Disclosure

• Presenter: Robert Bechara

- Relationships that may introduce potential bias and/or conflict of interest:
 - Grants/Research Support: Pentax
 - Speakers Bureau/Honoraria: Olympus
 - Consulting Fees: Olympus
 - Other:


Objectives



- Appreciate the appearance of the normal gastric mucosa
 - Microsurface (MS) and microvasculature(MV)
- Be able to distinguish between normal and neoplastic gastric mucosa
- Be aware of the endoscopic appearance, management & follow-up of:
 - Early gastric cancer (EGC)
 - Fundic gland polyps (FGP)
 - Hyperplastic polyps (HP)
 - Gastric adenomas (GA)
 - Neuroendocrine Tumors (NET)

Normal Gastric Mucosa






Microstructure-Body/fundus




Microstructure- Antrum



Characterizing Gastric Lesions-VS Classification

- Demarcation line (DL)
 - Present/Absent

- Microvasculature (MV): SECN, CV
 - Regular/Irregular/Absent



- Microsurface (MS): CO, MCE
 - Regular/Irregular/Absent





1. Group

a) Irregular vessel arrangement, shading, morphology, distribution, directionality

2. Individual


a) Unequal sizes/shape/caliber/shades/loops and irregular branches





- Within the lesion, the MCE and IP
 - Do not show a regular repeating pattern

- The MCE distribution and arrangement are also non-uniform
 - Lengths and widths not uniform
 - Breaks and interruptions
 - Asymmetrical distribution and irregular arrangement




Clinical

Endoscopic Appearance Management Follow-up

Gastric Cancer


- In US CRC incidence is 17-23 per 100 000/year
- Mongolia/South Korea/China/Japan gastric Cancer incidence up to 20-40 per 100 000 per year
- Risk Factors
 - Family Hx, atrophic gastritis, intestinal metaplasia, dysplasia, high risk ethnicity

- Location
 - Anywhere
- Macroscopic
 - Any: Paris Ila/b/c (most common)
- Microscopic
 - Demarcation line with IMVP and/or IMSP
 - *same principle for Barretts*









- Management
 - EGC and all gastric dysplasia should be resected en bloc
 - < 1cm EMR
 - >1cm ESD


• Ensure thorough assessment of background mucosa with image enhanced

endoscopy (IEE) +Sydney protocol for mapping Bx

• Incidence of synchronous dysplasia 30%




Clinical
Endoscopic Appearance
Management
Follow-up




Nakamoto, S. et al. Indications for the use of EMR for early gastric cancer in Japan: a comparative study with ESD. Endoscopy **41**, 746-750, (2009)


Carmack, S. et al. Management of gastric polyps: a pathology-based guide for gastroenterologists. Nature reviews. Gastroenterology & hepatology **6**, 331-341, (2009).

- After curative resection (R0),
 - Patient should undergo follow-up EGD in 6-12 months
 - Surveillance q1year with image enhanced endoscopy



- If non-curative resection
 - Repeat EMR/ESD (if lateral margin +)
 - Surgical resection (if vertical margin +ve due to deep submucosal invasion, unfavorable histology)






- Most common polyps encountered
 - ~5% of patients undergoing endoscopy
 - ~75% of all polyps encountered
- Clinical
 - Sporadic
 - PPI-induced
 - FAP
- Risk of dysplasia
 - Overall <1% in sporadic/PPI
 - if>1cm ~2%
 - FAP-up to 40% can have dysplasia





- Location
 - Body

- Macroscopic
 - Paris Isp/p/s
 - Smooth, shiny, no exudates, prominent CVs
- Microscopic
 - Have similar MV and MS as normal gastric body



• Document: size, number, location



- If:
 - <1cm→ representative bx
 - >1cm -> generally recommend resection
 - >20, LGD or duodenal adenomas
 - Sample based on above and also C-scope
- Resection tips*
 - Use a thicker, braided snare (offers more coagulation)
 - Ensure you get snare to base of FGP (can be aided by injection)
 - Careful around the stalk may cold cut through → minor bleeding

Clinical
Endoscopic Appearance
Management
Follow-up

Generally do not require follow-up

- Patients with FAP should be have surveillance EGD due to the increased risk of gastric neoplasia
 - Interval q1-5 years depending on Spigelman classification








Clinical
Endoscopic Appearance
Management
Follow-up

Second most common type gastric polyp

- Usually as result of recurring insult
 - Chronic gastritis (chemical, reactive, H.pylori), portal HTN
- Risk of dysplasia
 - ~2-20%
- Risk of carcinoma ~0.5-2%




Clinical **Endoscopic Appearance** Management Follow-up

- Location
 - Anywhere in the stomach, but are more common in the antrum



- Paris Is/sp/p
- Can be friable with overlying mucin, surface erosions
- Microscopic
 - Very dense vascular structure, with elongated/villous microsurface



Ahn, J. Y. et al. Neoplasms arising in large gastric hyperplastic polyps: endoscopic and pathologic features. Gastrointestinal endoscopy 80, 1005-1013.e1002, (2014).

Clinical
Endoscopic Appearance
Management
Follow-up

• <1cm representative sample via bx</p>


- If >1cm generally resect
 - If <3cm and known H.P +ve, recommend eradication and repeat EGD 3-6 months prior to resection as likely to regress
 - If >3cm, resect regardless of H.P status as unlikely to regress
- Thorough assessment of background mucosa with IEE + Sydney protocol for mapping Bx

- Resection tips*
 - Submucosal Injection +/- epi
 - For Paris Ip/Isp lesions, use a thicker, braided snare
 - For Paris Is lesions >3cm, use a thinner snare to increase current density as tend to have +++ fibrosis and current may not conduct current well
 - piecemeal removal, ESD or limited ESD with snare ("hybrid ESD")
 - Be prepared for hemostasis

Clinical
Endoscopic Appearance
Management
Follow-up

- If removed piecemeal and/or if inciting factor not removed tend recur
 - Repeat EGD in 1 year

 Surveillance is recommended if there is evidence of dysplasia, atrophy or intestinal metaplasia






Islam, R. S., Patel, N. C., Lam-Himlin, D. & Nguyen, C. C. Gastric polyps: a review of clinical, endoscopic, and histopathologic features and management decisions. *Gastroenterol Hepatol (N Y)* 9, 640-651 (2013).



Most common neoplastic polyp



Clinical
Endoscopic Appearance
Management
Follow-up

• Typically associated with H.pylori, atrophic gastritis, intestinal metaplasia

High incidence of synchronous dysplastic lesions up to ~30%

- Risk of carcinoma
 - For >2cm up to 40%



Location:

Anywhere, more common in antrum



Clinical

Endoscopic Appearance

Management

Follow-up

Macroscopic

- Elevated "velvety", lesion similar appearance to duodenal adenomas
- Usually Paris Is, IIa, +/-IIc component
- If >2cm, have IIc component → Think EGC

Microscopic

- No unified accepted classification
- +demarcation line, MS and MV are different from surrounding mucosa, but generally regular



Rugge M, Farinati F, Baffa R, et al. Gastric epithelial dysplasia in the natural history of gastric cancer: A multicenter prospective follow-up study. Gastroenterology 1994;107:1288-1296. Yao, K. et al. White opaque substance within superficial elevated gastric neoplasia as visualized by magnification endoscopy with narrow-band imaging: a new optical sign for differentiating between adenoma and carcinoma. Gastrointestinal endoscopy 68, 574-580, (2008).


- Management
 - EMR or ESD, ideally gastric adenomas should be resected en bloc
 - < 1cm EMR
 - >1cm ESD



- Thorough assessment of background mucosa with IEE + Sydney protocol for mapping Bx
 - Incidence of synchronous dysplasia 30%

- If enbloc R0 resection with clear margins and only LGD
 - EGD in 1 year with image enhanced endoscopy, then q1-3 years

- R0 resection with HGD
 - EGD in 6months
- If piecemeal/incomplete resection
 - Repeat EGD 3 months





Clinical
Endoscopic Appearance
Management
Follow-up

Make up less than 1% of detected gastric polyps

- 3 Types
 - Type I ~80%
 - Usually multiple and small <1cm, associated with hypergastrinemia 2° to atrophic gastritis
 - Usually, incidental finding on EGD done for anemia
 - **Type II** ~5%
 - Usually multiple and small <1cm, result from gastrin secreting tumor
 - Often detected as part of workup for MEN-1 or ZES
 - **Type III** ~15%
 - Often present as sporadic, usually solitary lesions
 - Usually detected after become larger >1.5cm), tend to have higher grade and poorer prognosis



- Type I, II: clusters in body/fundus
- Type III: Solitary anywhere





- Marcoscopic
 - Paris Is, Ila, +/-Ilc component
- Microscopic
 - Usually have normal/stretched mucosal/vasculature at periphery with central areas having IMVP/IMSP

Endoscopic Appearance

Clinical


Management Follow-up

Type I,II

- Can Bx if small(<1cm) and few, EMR also reasonable.
 - Sample "normal" gastric mucosa to assess for atrophic gastritis
- Usually can be resected with traditional EMR/ESD
- Can consider antrectomy in type I

Type III


- More often require surgery due to presenting at later stage with metastasis
- Can consider EMR/ESD if no evidence metastasis or muscularis propria involvement
- *Should be discussed at multidisciplinary tumor boards
- For larger lesions (>1cm), PET-CT, EUS and discussion at multidisciplinary tumor boards



- Resection tips*
 - Submucosal Injection +/- epi
 - For the larger lesions (>1cm) tend to have submucosal invasion, fibrosis and fat
 - Will take longer to cut through (if EMR)
 - Vascular so be prepared to deal with bleeding.

- Type I, II,
 - If favorable pathology surveillance with annual EGD
 - Borderline/unfavorable pathology should discuss at multidisciplinary tumor boards

- Type III
 - Usually managed surgically
 - Should discuss at multidisciplinary tumor boards if endoscopically resected



General Tips for Gastric Tissue Resection

Diagnostic

- Clean the stomach well and identify landmarks.
- Macroscopic and microscopic exam of lesion \rightarrow Pay close attention to margins
- Examine the background mucosa

Planning therapy

- Forward and retroflexed: assess stability and maneuverability
- Am I the right person for this or should I refer to another endoscopist?
- Is now the right time?
 - If bleeds acutely what is plan A, B, C?
 - Review the plan, tools and specific language with your assistant
 - Make sure you have all your tools

Practical Tips for Gastric Tissue Resection

Therapeutic

- Injection:
 - Most gastric lesions with saline +/- dilute epi. Viscous agent if larger/fibrosis/scarred
- Electrosurgery:
 - Most common setting ERBE EndoCut Q (Effect 3, Duration 1, Interval 6)
- Snares:
 - Thicker braided snare for more coagulation easier control (Olympus snaremaster 15mm)
 - Stiffer, thinner twisted snares for lesions with fibrosis/difficult to capture (Boston captivator II, Cook Acusnare hexagonal, US Endoscopy Lariet)

Practical Tips for Gastric Tissue Resection

Hemostasis:

- You must be comfortable with bleeding
- Coagulation forceps (Soft Coag Effect 5, 80W)
 - consider cautious application of Endoloop for >2cm 1SP, 1P polyps.
- Close defects if possible.

Summary

- Normal gastric microsurface (MS) and microvasculature(MV) and key features to distinguish between normal and neoplastic lesions
- Endoscopic appearance, management and follow-up of:
 - Early gastric cancer (EGC)
 - Fundic gland polyps (FGP)
 - Hyperplastic polyps (HP)
 - Gastric adenomas (GA)
 - Neuroendocrine Tumors (NET)
- Tips for gastric tissue resection

Thank you!

